medigraphic.com
ISSN 1025-0255 (Electronic)

2019, Number 3

<< Back

AMC 2019; 23 (3)

Diagnostic criteria and new therapeutic options for patients diagnosed with non-Hodgkin lymphoma

Moreno-Laguard Y, Laguna-Salvia L, Larquin-Comet JI, León-Ramentol CC, Hernandez-Soler YF, González-Basulto MJ

Language: Spanish
References: 22
Page: 415-426
PDF size: 513.70 Kb.


ABSTRACT

Background: malignant haemopathies increase their incidence and proliferation within the population, among them the lymphoproliferative syndrome occupies an important place, it is a group of disorders of clonal origin, which affects the lymphoid cells, with heterogeneous characteristics from the point of clinical, histological and molecular view.
Objective: to group different diagnostic criteria and to disclose new therapeutic options for patients diagnosed with non-Hodgkin's lymphoma.
Methods: a bibliographic search was carried out in the access platforms to databases of the Infomed Cuban health information network, within them in EBSCOhost, PubMed / Medline and SciELO. The following descriptors were used: lymphoproliferative syndromes, lymphomas, non-Hodgkin's lymphoma.
Results: the historical evolution of the lymphoproliferative syndromes is addressed from its initial description to the present time, as well as the different classifications, the conventional treatments used and an overview of the research carried out in search of new treatments.
Conclusions: the classification of non-Hodgkin lymphomas has changed over time; the extent of the disease has a fundamental role in the selection of treatment and possible survival of the patient. There is a wide variety of promising developing agents available for the treatment of follicular lymphoma.


REFERENCES

  1. Freedman AS, Jacobson CA, Mauch P, Aster JC. Non-Hodgkin’s lymphoma. En: DeVita VT, Law-rence TS, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology. 10th ed. Philadelphia, Pa: Wolters Kluwer; 2015.p.1552-1583.

  2. Kass EH. Thomas Hodgkin, Physician and social scientist. Guys Hosp Rep. 1966;115(3):269-80.

  3. Roschewski MJ, Wilson WH. Non-Hodgkin Lymphoma. En: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, editors. Abeloff’s Clinical Oncology. 5th ed. Philadelphia, Pa: Elsevier; 2014.p.2033-2059.

  4. Noya Chaveco ME, Moya González NL. Roca Goderich. Temas Medicina Interna. T III. 5ta ed. La Habana:ECIMED;2017.

  5. Vicente Peña E, Vicente Sánchez BM. Enfermedades del sistema hemolinfopoyético. Linfomas. En: Vicente Peña E, editor. Medicina Interna. Diagnóstico y tratamiento. La Habana: ECIMED; 2016.p. 497-498.

  6. Alonso Mariño OL, Alonso Mariño AL, Miranda Chaviano J. Caracterización clínico-epidemiológica de los linfomas en un período de cinco años en Villa Clara. Medicent Electrón [Internet]. 2015 [citado 01 Abr 2019];19(1):[aprox. 6 p.]. Disponible en: http://www.medigraphic.com/pdfs/medicentro/cmc-2015/cmc151c.pdf

  7. Cairo MS, Pinkerton R. Childhood, adolescent and young adult non-Hodgkin lymphoma: state of the science. Br J Haematol. 2016;173:507-30.

  8. Quintero Ordoñez DI. Linfoma No Hodgkin Difuso de células Grandes B. Rev Med Costa Rica Cen. 2014;71(610):333–338.

  9. Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, et al. An en-hanced International Prognostic Index (NCCN-IPI) for patients with diffuse B-cell lymphoma treated in the rituximab era. Blood. 2014;123:837-842.

  10. Swedlow SH, Campo E, Harris NL. Classification of Tumors of Haematopoietic and Lymphoid Tis-sues. 4th ed. Lyon, France; IARC Press;2008.

  11. Campo E, Swerdlow SH, Harris NL. The 2008 WHO classification of lymphoid neoplasms and be-yond: evolving concepts and practical applications. Blood. 2011;117:5019-32.

  12. Cheson B, Fisher R, Barringston S, Cavalli F, Schwartz L, Zucca E, Lister TA. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and NonHodgkin Lymphoma: The Lugano Classification. J Clin Oncol. 2014;32(27):3059-3067.

  13. Sandlund JT, Guillerman RP, Perkins SL. International Non-Hodgkin Lymphoma Response Crite-ria. J Clin Oncol. 2015;33:2106-11.

  14. Castellanos Sinco H, Ramos Peñafiel C, Rivas Vera S, Kassack Ipiña JJ, Martínez Murillo C, Colla-zo Jaloma J, et al. Características clínico epidemiológicas y de laboratorio de los linfomas no Hodgkin en el hospital general de México (HGM). Rev Hematol Mex. 2014;15(Supl.1):179-80.

  15. Yamaguchi M. The anti-apoptotic effect of regucalcin is mediated through multi-signaling path-ways. Apoptosis. 2013;18(10):1145-1153. 516. Correia C, Lee S-H, Meng XW, Vincelette ND, Knorr KLB, Ding H, et al. Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment. Biochim Biophys Acta. 2015;1853(7):1658-1671.

  16. Castellanos Sinco H, Ramos Peñafiel C, Santoyo Sánchez A, Collazo Jaloma J, Martínez Murillo C, Montaño Figueroa E, et al. Linfomas no hodgkin algunos tópicos sobre genética y patogenia molecu-lar. Rev Venez Oncol. 2016;28(2):121-134.

  17. Arcaini L, Merli M, Passamonti F. Validation of follicular lymphoma international prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients. Br J Haematol. 2010;149(3):455-7.

  18. Luminari S, Bellei M, Biasoli I, Federico M. Follicular lymphoma: treatment and prognostic factors. Rev Bras Hematol Hemoter [Internet]. 2012 [citado 06 Mar 2019];34(1):[aprox. 5 p.]. Disponible en: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842012000100015&lng=en

  19. Tse E, Kwong YL. Recent Advances in the Treatment of Lymphomas. J Hong Kong Col Radiol. 2010;13(Suppl):S22-4.

  20. Panizo Santos C, Inogés Sancho S, García Muñoz R, Bendandi M. Tratamiento de los linfomas foli-culares. Cuadernos de Hematología [Internet]. Pamplona, Navarra: Clínica Universidad de Navarra; 2012 [citado 06 Mar 2019]. Disponible en: http://www.leucemiaylinfoma.com/modulos/CH/2013/Capitulo_3-I_2013.pdf

  21. Vargo JA, Gill BS, Balasubramani GK, Beriwal S. What is the optimal management of early- stage low-grade follicular lymphoma in the modern era? Cancer. 2015;121(18):3325-34.

  22. Hiddeman W, Unterhalt M, Pott C. Fludarabine single agent therapy for relapsed low grade non-Hodgkin´s lymphoma: a phase II study of the German Low-Grade Non-Hodgkin´s Lymphoma Study Group: Semin. 2003;20(Suppl 7):28-31.




2020     |     www.medigraphic.com